-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicine Net, April 20th, these medicines are out of stock?
18 drugs, difficult to purchase
Today (April 19), Jinyi Pharmaceutical's official website released an announcement of difficult-to-purchase varieties.
The announcement showed that two varieties of calcium carbonate tablets and dexmedetomidine hydrochloride injection had difficulties in purchasing.
In addition, the announcement also attached information on the varieties that were difficult to purchase in the early stage, involving a total of 16 varieties.
The specific list is as follows:
In addition, the announcement also attached information on the varieties that were difficult to purchase in the early stage, involving a total of 16 varieties.
The specific list is as follows:
According to the company's official website, Zhejiang Jinyi Pharmaceutical Co.
, Ltd.
was established on July 7, 2006, funded and established by Jinhua Central Hospital .
The company's main business is the wholesale and retail of pharmaceuticals and medical products.
Headquartered in Jinhua, Zhejiang, with a registered capital of 5 million yuan.
, Ltd.
was established on July 7, 2006, funded and established by Jinhua Central Hospital .
The company's main business is the wholesale and retail of pharmaceuticals and medical products.
Headquartered in Jinhua, Zhejiang, with a registered capital of 5 million yuan.
Judging from this information, the company’s announcement of difficult-to- pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase products may involve hospital channels or retail channels.
But from the analysis of the types of varieties, it should be the majority of hospital channels.
com.
cn/news/yyzb/" target="_blank">purchase products may involve hospital channels or retail channels.
But from the analysis of the types of varieties, it should be the majority of hospital channels.
Nationally sourced varieties, in the list?
It is worth noting that among the varieties that have been announced to be difficult to purchase, there is dexmedetomidine hydrochloride injection.
Everyone knows that this variety is a 4+7 variety purchased with volume, but the selected specification for volume purchasing is 2ml: 0.
2mg, and the specification that is difficult to purchase here is 1ml: 0.
1mg.
Everyone knows that this variety is a 4+7 variety purchased with volume, but the selected specification for volume purchasing is 2ml: 0.
2mg, and the specification that is difficult to purchase here is 1ml: 0.
1mg.
Speaking of dexmedetomidine hydrochloride injection, there is a lot of attention in the 4+7 volume purchase.
The company selected at that time was Yangtze River.
The country has not yet released an implementation date.
The 4+7 price of this product was the first to land in Shandong and Gansu provinces.
The company selected at that time was Yangtze River.
The country has not yet released an implementation date.
The 4+7 price of this product was the first to land in Shandong and Gansu provinces.
In the 4+7 contract extension, dexmedetomidine hydrochloride injection once again became the focus of discussion in the industry.
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
Kelun Pharmaceutical became the newly selected company for the contract renewal.
Compared with the original winning bidder, Kelun Pharmaceutical's dexmedetomidine hydrochloride injection dropped by 93.
61%, and the price was 8.
5 yuan per bottle.
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
Kelun Pharmaceutical became the newly selected company for the contract renewal.
Compared with the original winning bidder, Kelun Pharmaceutical's dexmedetomidine hydrochloride injection dropped by 93.
61%, and the price was 8.
5 yuan per bottle.
According to industry analysis, in the renewal phase of the national centralized procurement, the competition for some varieties is still very fierce.
Like Kelun Pharmaceutical's dexmedetomidine hydrochloride injection, it passed the consistency evaluation not long ago.
It can be seen that this also means that among the national sourcing products, the subsequent over-assessment enterprises have a certain chance to impact the bid-winning enterprises, and some products will still face the crisis of being replaced even if they win the bid in centralized sourcing.
Like Kelun Pharmaceutical's dexmedetomidine hydrochloride injection, it passed the consistency evaluation not long ago.
It can be seen that this also means that among the national sourcing products, the subsequent over-assessment enterprises have a certain chance to impact the bid-winning enterprises, and some products will still face the crisis of being replaced even if they win the bid in centralized sourcing.
As for the above announcement, why dexmedetomidine hydrochloride injection has become a difficult product to purchase, the real reason is not yet known.
However, this seems to reflect a problem, which is the problem of market supply and demand that may be brought about by the selection of nationally sourced varieties and subsequent competition.
However, this seems to reflect a problem, which is the problem of market supply and demand that may be brought about by the selection of nationally sourced varieties and subsequent competition.
For each batch of national procurement, the follow-up will face the problem of contract renewal.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
At present, in addition to advancing the fifth batch of national procurement, the renewal of the previous batches is a top priority.
How to renew the contract for nationally sourced varieties? There are two methods that are currently discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
How to renew the contract for nationally sourced varieties? There are two methods that are currently discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
The industry believes that these national procurement renewals will bring market opportunities for newly reviewed companies, but the entire market may also usher in greater changes.
Medicine Net, April 20th, these medicines are out of stock?
18 drugs, difficult to purchase
Today (April 19), Jinyi Pharmaceutical's official website released an announcement of difficult-to-purchase varieties.
The announcement showed that two varieties of calcium carbonate tablets and dexmedetomidine hydrochloride injection had difficulties in purchasing.
In addition, the announcement also attached information on the varieties that were difficult to purchase in the early stage, involving a total of 16 varieties.
The specific list is as follows:
In addition, the announcement also attached information on the varieties that were difficult to purchase in the early stage, involving a total of 16 varieties.
The specific list is as follows:
According to the company's official website, Zhejiang Jinyi Pharmaceutical Co.
, Ltd.
was established on July 7, 2006, funded and established by Jinhua Central Hospital .
The company's main business is the wholesale and retail of pharmaceuticals and medical products.
Headquartered in Jinhua, Zhejiang, with a registered capital of 5 million yuan.
, Ltd.
was established on July 7, 2006, funded and established by Jinhua Central Hospital .
The company's main business is the wholesale and retail of pharmaceuticals and medical products.
Headquartered in Jinhua, Zhejiang, with a registered capital of 5 million yuan.
Judging from this information, the company’s announcement of difficult-to- pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase products may involve hospital channels or retail channels.
But from the analysis of the types of varieties, it should be the majority of hospital channels.
com.
cn/news/yyzb/" target="_blank">purchase products may involve hospital channels or retail channels.
But from the analysis of the types of varieties, it should be the majority of hospital channels.
Nationally sourced varieties, in the list?
It is worth noting that among the varieties that have been announced to be difficult to purchase, there is dexmedetomidine hydrochloride injection.
Everyone knows that this variety is a 4+7 variety purchased with volume, but the selected specification for volume purchasing is 2ml: 0.
2mg, and the specification that is difficult to purchase here is 1ml: 0.
1mg.
Everyone knows that this variety is a 4+7 variety purchased with volume, but the selected specification for volume purchasing is 2ml: 0.
2mg, and the specification that is difficult to purchase here is 1ml: 0.
1mg.
Speaking of dexmedetomidine hydrochloride injection, there is a lot of attention in the 4+7 volume purchase.
The company selected at that time was Yangtze River.
The country has not yet released an implementation date.
The 4+7 price of this product was the first to land in Shandong and Gansu provinces.
The company selected at that time was Yangtze River.
The country has not yet released an implementation date.
The 4+7 price of this product was the first to land in Shandong and Gansu provinces.
In the 4+7 contract extension, dexmedetomidine hydrochloride injection once again became the focus of discussion in the industry.
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
Kelun Pharmaceutical became the newly selected company for the contract renewal.
Compared with the original winning bidder, Kelun Pharmaceutical's dexmedetomidine hydrochloride injection dropped by 93.
61%, and the price was 8.
5 yuan per bottle.
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
Kelun Pharmaceutical became the newly selected company for the contract renewal.
Compared with the original winning bidder, Kelun Pharmaceutical's dexmedetomidine hydrochloride injection dropped by 93.
61%, and the price was 8.
5 yuan per bottle.
According to industry analysis, in the renewal phase of the national centralized procurement, the competition for some varieties is still very fierce.
Like Kelun Pharmaceutical's dexmedetomidine hydrochloride injection, it passed the consistency evaluation not long ago.
It can be seen that this also means that among the national sourcing products, the subsequent over-assessment enterprises have a certain chance to impact the bid-winning enterprises, and some products will still face the crisis of being replaced even if they win the bid in centralized sourcing.
Like Kelun Pharmaceutical's dexmedetomidine hydrochloride injection, it passed the consistency evaluation not long ago.
It can be seen that this also means that among the national sourcing products, the subsequent over-assessment enterprises have a certain chance to impact the bid-winning enterprises, and some products will still face the crisis of being replaced even if they win the bid in centralized sourcing.
As for the above announcement, why dexmedetomidine hydrochloride injection has become a difficult product to purchase, the real reason is not yet known.
However, this seems to reflect a problem, which is the problem of market supply and demand that may be brought about by the selection of nationally sourced varieties and subsequent competition.
However, this seems to reflect a problem, which is the problem of market supply and demand that may be brought about by the selection of nationally sourced varieties and subsequent competition.
For each batch of national procurement, the follow-up will face the problem of contract renewal.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
At present, in addition to advancing the fifth batch of national procurement, the renewal of the previous batches is a top priority.
How to renew the contract for nationally sourced varieties? There are two methods that are currently discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
How to renew the contract for nationally sourced varieties? There are two methods that are currently discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
The industry believes that these national procurement renewals will bring market opportunities for newly reviewed companies, but the entire market may also usher in greater changes.
Medicine Net, April 20th, these medicines are out of stock?
18 drugs, difficult to purchase
18 drugs, difficult to purchase Today (April 19), Jinyi Pharmaceutical's official website released an announcement of difficult-to-purchase varieties.
Medicine Medicine Medicine The announcement showed that two varieties of calcium carbonate tablets and dexmedetomidine hydrochloride injection had difficulties in purchasing.
In addition, the announcement also attached information on the varieties that were difficult to purchase in the early stage, involving a total of 16 varieties.
The specific list is as follows:
In addition, the announcement also attached information on the varieties that were difficult to purchase in the early stage, involving a total of 16 varieties.
The specific list is as follows:
According to the company's official website, Zhejiang Jinyi Pharmaceutical Co.
, Ltd.
was established on July 7, 2006, funded and established by Jinhua Central Hospital .
The company's main business is the wholesale and retail of pharmaceuticals and medical products.
Headquartered in Jinhua, Zhejiang, with a registered capital of 5 million yuan.
Hospital hospital hospital medicine medicine medicine, Ltd.
was established on July 7, 2006, funded and established by Jinhua Central Hospital .
The company's main business is the wholesale and retail of pharmaceuticals and medical products.
Headquartered in Jinhua, Zhejiang, with a registered capital of 5 million yuan.
Judging from this information, the company’s announcement of difficult-to- pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase products may involve hospital channels or retail channels.
But from the analysis of the types of varieties, it should be the majority of hospital channels.
pharmnet. com.
cn/news/yyzb/" target="_blank">purchase products may involve hospital channels or retail channels.
But from the analysis of the types of varieties, it should be the majority of hospital channels.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
Nationally sourced varieties, in the list?
Nationally sourced varieties, in the list? It is worth noting that among the varieties that have been announced to be difficult to purchase, there is dexmedetomidine hydrochloride injection.
Everyone knows that this variety is a 4+7 variety purchased with volume, but the selected specification for volume purchasing is 2ml: 0.
2mg, and the specification that is difficult to purchase here is 1ml: 0.
1mg.
Everyone knows that this variety is a 4+7 variety purchased with volume, but the selected specification for volume purchasing is 2ml: 0.
2mg, and the specification that is difficult to purchase here is 1ml: 0.
1mg.
Speaking of dexmedetomidine hydrochloride injection, there is a lot of attention in the 4+7 volume purchase.
The company selected at that time was Yangtze River.
The country has not yet released an implementation date.
The 4+7 price of this product was the first to land in Shandong and Gansu provinces.
Enterprise business enterpriseThe company selected at that time was Yangtze River.
The country has not yet released an implementation date.
The 4+7 price of this product was the first to land in Shandong and Gansu provinces.
In the 4+7 contract extension, dexmedetomidine hydrochloride injection once again became the focus of discussion in the industry.
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
Kelun Pharmaceutical became the newly selected company for the contract renewal.
Compared with the original winning bidder, Kelun Pharmaceutical's dexmedetomidine hydrochloride injection dropped by 93.
61%, and the price was 8.
5 yuan per bottle.
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
Kelun Pharmaceutical became the newly selected company for the contract renewal.
Compared with the original winning bidder, Kelun Pharmaceutical's dexmedetomidine hydrochloride injection dropped by 93.
61%, and the price was 8.
5 yuan per bottle.
According to industry analysis, in the renewal phase of the national centralized procurement, the competition for some varieties is still very fierce.
Like Kelun Pharmaceutical's dexmedetomidine hydrochloride injection, it passed the consistency evaluation not long ago.
It can be seen that this also means that among the national sourcing products, the subsequent over-assessment enterprises have a certain chance to impact the bid-winning enterprises, and some products will still face the crisis of being replaced even if they win the bid in centralized sourcing.
Like Kelun Pharmaceutical's dexmedetomidine hydrochloride injection, it passed the consistency evaluation not long ago.
It can be seen that this also means that among the national sourcing products, the subsequent over-assessment enterprises have a certain chance to impact the bid-winning enterprises, and some products will still face the crisis of being replaced even if they win the bid in centralized sourcing.
As for the above announcement, why dexmedetomidine hydrochloride injection has become a difficult product to purchase, the real reason is not yet known.
However, this seems to reflect a problem, which is the problem of market supply and demand that may be brought about by the selection of nationally sourced varieties and subsequent competition.
However, this seems to reflect a problem, which is the problem of market supply and demand that may be brought about by the selection of nationally sourced varieties and subsequent competition.
For each batch of national procurement, the follow-up will face the problem of contract renewal.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
At present, in addition to advancing the fifth batch of national procurement, the renewal of the previous batches is a top priority.
How to renew the contract for nationally sourced varieties? There are two methods that are currently discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
How to renew the contract for nationally sourced varieties? There are two methods that are currently discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
The industry believes that these national procurement renewals will bring market opportunities for newly reviewed companies, but the entire market may also usher in greater changes.
